var addressPoints = [
  [
    "Integrative clinical, genomic, transcriptomic, and immunopathologic characterization of circulating KIM-1<br />Kidney Cancer Research Summit (KCRS) 2025; Boston, MA, USA",
    42.3588336,
    -71.0578303
  ],
  [
    "KIM-1 as a circulating biomarker in metastatic RCC: Post-hoc analysis of JAVELIN Renal 101<br />ASCO Genitourinary Cancers Symposium 2025; San Francisco, CA, USA",
    37.7879363,
    -122.4075201
  ],
  [
    "Perspectives on knowledge, precautionary behaviors, and psychological status of patients with cardiovascular diseases during the first wave of the COVID-19 pandemic in Lebanon<br />Demystifying COVID-19: Lessons Learned and Future Opportunities; Beirut, Lebanon",
    33.8892265,
    35.5025585
  ],
  [
    "ERBB2 amplifications across sex, race, and cancer types<br />ESMO Congress 2024; Barcelona, Spain",
    41.3825802,
    2.177073
  ],
  [
    "ERBB2 mutations and association with molecular phenotype in urothelial carcinoma<br />ASCO Annual Meeting 2024; Chicago, IL, USA",
    41.8755616,
    -87.6244212
  ],
  [
    "Implementing Biomarkers of Immunotherapy for Genitourinary Cancers<br />SITC Workshop; Boston, MA, USA",
    42.3588336,
    -71.0578303
  ],
  [
    "KIM-1 as a circulating biomarker in metastatic RCC: Post-hoc analysis of JAVELIN Renal 101<br />OncLive National Fellows Forum: Genitourinary Cancers; San Francisco, CA, USA",
    37.7879363,
    -122.4075201
  ],
  [
    "Pan-tumor multicenter study of the impact of prior immune-related adverse events (irAEs) on safety and efficacy of subsequent antibody-drug conjugate (ADC)<br />Society for Immunotherapy of Cancer (SITC); National Harbor, MD, USA",
    38.789356,
    -77.0066308
  ],
  [
    "Integrative clinical, genomic, and transcriptomic characterization of circulating KIM-1 in metastatic RCC<br />ASCO Annual Meeting 2025; Chicago, IL, USA",
    41.8755616,
    -87.6244212
  ],
  [
    "Inhibition of AXL along with c-Met overcomes resistance development in renal cell carcinoma<br />Kidney Cancer Research Symposium 2024; Boston, MA, USA",
    42.3588336,
    -71.0578303
  ],
  [
    "Host immune signatures as predictors of response to immunotherapy-based regimens in metastatic renal cell carcinoma<br />OncLive National Fellows Forum: Genitourinary Cancers; San Francisco, CA, USA",
    37.7879363,
    -122.4075201
  ],
  [
    "Soluble MAdCAM-1 predicts outcomes in patients with metastatic renal cell carcinoma: results from three independent clinical trials<br />ESMO Congress 2025; Berlin, Germany",
    52.5173885,
    13.3951309
  ]
];